Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) Shares Shorted: Short Interest Down 50.2% in September

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totaling 947,657 shares, a decline of 50.2% from the September 15th total of 1,904,283 shares. Based on an average daily trading volume, of 26,546,756 shares, the days-to-cover ratio is currently 0.0 days. Currently, 11.7% of the company’s shares are sold short.

Mymd Pharmaceuticals Price Performance

Shares of NASDAQ QCLS traded down $0.01 during midday trading on Wednesday, hitting $0.53. The company’s stock had a trading volume of 95,492 shares, compared to its average volume of 2,124,176. The company’s fifty day moving average price is $1.67. Mymd Pharmaceuticals has a 1 year low of $0.42 and a 1 year high of $8.17. The stock has a market capitalization of $4.36 million, a price-to-earnings ratio of -0.15 and a beta of 2.32.

Mymd Pharmaceuticals (NASDAQ:QCLS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) earnings per share for the quarter.

Analyst Ratings Changes

QCLS has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday, August 7th. Wall Street Zen raised Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases, inflammation and age-related conditions. The company has historically pursued treatments designed to regulate the immune system and address biological processes associated with chronic disease and aging.

MyMD’s principal investigational product has been MYMD-1, an orally administered small-molecule therapy intended to modulate immune and inflammatory responses.